Valeant Pharmaceuticals International Inc. (VRX)

22.07
0.07 0.32
NYSE : Health Technology
Prev Close 22.14
Open 22.40
Day Low/High 21.94 / 22.59
52 Wk Low/High 10.94 / 24.43
Volume 4.70M
Avg Volume 9.69M
Exchange NYSE
Shares Outstanding 348.84M
Market Cap 7.52B
EPS 6.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer on Bausch Health: This Stock Is a Buy

Jim Cramer on Bausch Health: This Stock Is a Buy

Valeant Pharmaceuticals is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Video: Jim Cramer on Oil, Occidental Petroleum, Bausch Health and Etsy

Video: Jim Cramer on Oil, Occidental Petroleum, Bausch Health and Etsy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

Emotions Are Running This Market: Cramer's 'Mad Money' Recap (Tuesday 5/8/18)

Emotions Are Running This Market: Cramer's 'Mad Money' Recap (Tuesday 5/8/18)

Jim Cramer says the reason this market is so hard to deal with is that it doesn't know how to calculate an event -- even when everyone saw it coming.

Dow Trims Earlier Losses, Finishes Slightly Higher After Volatile Session

Dow Trims Earlier Losses, Finishes Slightly Higher After Volatile Session

Stocks finished mixed on Tuesday after President Trump announced that the U.S. would withdraw from the Iran nuclear deal.

Video: Jim Cramer on the Iran Deal Decision, Hain Celestial & Caterpillar

Video: Jim Cramer on the Iran Deal Decision, Hain Celestial & Caterpillar

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.

Short Seller Andrew Left Says Square Is a 'Collection of Yawn Businesses'

Short Seller Andrew Left Says Square Is a 'Collection of Yawn Businesses'

Wall Street is 'drunk on bitcoin nonsense,' Left says. He tells TheStreet why his Citron Research is taking an unpopular stance on Square.

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Masco's 4% drop Thursday is the latest proof that big call buying doesn't mean insiders know something you don't.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

American Airlines, ABB Ltd., Salesforce.com: 'Mad Money' Lightning Round

American Airlines, ABB Ltd., Salesforce.com: 'Mad Money' Lightning Round

Jim Cramer focuses on American Airlines, Salesforce.com, Realty Income, Proctor & Gamble, United Bankshares, iRobot, Dominion Energy.

Rally Climbs on Earnings: Cramer's 'Mad Money' Recap (Thursday 4/12/18)

Rally Climbs on Earnings: Cramer's 'Mad Money' Recap (Thursday 4/12/18)

Good earnings reports, cooling oil, and tech leadership all contributed to Thursday's gains, says Jim Cramer. Along with no explosive presidential tweets.

Ready for Tesla's New Model Y? Here's When to Expect It

Ready for Tesla's New Model Y? Here's When to Expect It

Tesla's Model Y could begin production in November 2019, but don't get your hopes up.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Thursday.

Bill Ackman Needs a Big Win at ADP or Another Target to Stop the Bleeding

Bill Ackman Needs a Big Win at ADP or Another Target to Stop the Bleeding

The embattled activist is reportedly experiencing significant redemptions as investors seek to flee his fund. A campaign at the payroll processor in 2018 is a real possibility as Ackman has $500 million committed to a co-investment targeting the company

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Valeant Pharmaceuticals Is Back to Playing Defense

Valeant Pharmaceuticals Is Back to Playing Defense

What do the charts and indicators look like today? Let's check.

Could Valeant's Stock Blow Up by 40%?

Could Valeant's Stock Blow Up by 40%?

There are still skeptics when it comes to Valeant Pharmaceuticals -- and for good reason.

Dow Dives 380 Points, Posting Its First Losing February Since 2009

Dow Dives 380 Points, Posting Its First Losing February Since 2009

Stocks dropped on Wednesday as global investors parse potentially hawkish comments from Federal Reserve Chairman Jerome Powell and fourth-quarter GDP meets expectations.

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Politics, Davos, news -- none of it matters as much as earnings. Here's Jim Cramer's game plan for next week.

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Insurgent managers had another busy year. But behind the numbers there were some fascinating trends and surprising tactics. Here's our review of the year that was.

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.

TheStreet Quant Rating: C (Hold)